Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.24
CHRS's Cash-to-Debt is ranked lower than
78% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. CHRS: 1.24 )
Ranked among companies with meaningful Cash-to-Debt only.
CHRS' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.24  Med: 44.6 Max: No Debt
Current: 1.24
Equity-to-Asset 0.12
CHRS's Equity-to-Asset is ranked lower than
88% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. CHRS: 0.12 )
Ranked among companies with meaningful Equity-to-Asset only.
CHRS' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.05  Med: -0.03 Max: 0.36
Current: 0.12
-2.05
0.36
Piotroski F-Score: 3
Altman Z-Score: -0.07
Beneish M-Score: 5.02
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -60.98
CHRS's Operating Margin % is ranked higher than
54% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. CHRS: -60.98 )
Ranked among companies with meaningful Operating Margin % only.
CHRS' s Operating Margin % Range Over the Past 10 Years
Min: -2028.33  Med: -729.23 Max: -60.98
Current: -60.98
-2028.33
-60.98
Net Margin % -66.98
CHRS's Net Margin % is ranked higher than
52% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. CHRS: -66.98 )
Ranked among companies with meaningful Net Margin % only.
CHRS' s Net Margin % Range Over the Past 10 Years
Min: -1949.65  Med: -743.18 Max: -66.98
Current: -66.98
-1949.65
-66.98
ROA % -60.03
CHRS's ROA % is ranked lower than
71% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. CHRS: -60.03 )
Ranked among companies with meaningful ROA % only.
CHRS' s ROA % Range Over the Past 10 Years
Min: -145  Med: -111.74 Max: -60.03
Current: -60.03
-145
-60.03
ROC (Joel Greenblatt) % -1148.66
CHRS's ROC (Joel Greenblatt) % is ranked lower than
62% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. CHRS: -1148.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CHRS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2990.18  Med: -2679.87 Max: -1126.23
Current: -1148.66
-2990.18
-1126.23
GuruFocus has detected 3 Warning Signs with Coherus BioSciences Inc $CHRS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CHRS's 10-Y Financials

Financials (Next Earnings Date: 2017-06-13 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CHRS Guru Trades in Q1 2016

Steven Cohen 131,200 sh (New)
George Soros Sold Out
» More
Q2 2016

CHRS Guru Trades in Q2 2016

Paul Tudor Jones 11,300 sh (New)
Jim Simons 94,500 sh (New)
Steven Cohen 37,500 sh (-71.42%)
» More
Q3 2016

CHRS Guru Trades in Q3 2016

Joel Greenblatt 17,363 sh (New)
Steven Cohen Sold Out
Jim Simons Sold Out
Paul Tudor Jones 10,670 sh (-5.58%)
» More
Q4 2016

CHRS Guru Trades in Q4 2016

Steven Cohen 601,034 sh (New)
Joel Greenblatt 32,982 sh (+89.96%)
Paul Tudor Jones 14,396 sh (+34.92%)
» More
» Details

Insider Trades

Latest Guru Trades with CHRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 2836
Compare:NAS:ALDR, OTCPK:GNFTF, NAS:XNCR, NAS:CORT, NAS:AIMT, NAS:FPRX, NAS:FOLD, NAS:RGEN, NYSE:EBS, NAS:XLRN, NAS:ACOR, NAS:LOXO, OTCPK:PFSCF, OTCPK:BPMUF, NAS:EPZM, NAS:INSM, OTCPK:BVNRY, NAS:ASND, NAS:FWP, NAS:ESPR » details
Coherus BioSciences Inc is a late-stage clinical biologics platform company. The Company is engaged in developing biosimilar therapeutics.

Coherus BioSciences is a biotechnology company that develops biosimilar therapeutics. The company focuses on process science, analytical characterization, protein production, and clinical-regulatory development. Coherus' commercialization partnerships include global pharmaceutical companies in Europe, Asia, and Latin America. The company seeks to ensure successful drug development and manufacturing under very aggressive timelines. Coherus generates the vast majority of its revenue in the United States.

Top Ranked Articles about Coherus BioSciences Inc

Coherus Biosciences' Humira Petition Denied AbbVie’s Humira patent remains untouched
AbbVie’s (NYSE:ABBV) shareholders received positive news from the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office in regard to the legitimacy of AbbVie’s Humira formulation patent. Read more...

Ratios

vs
industry
vs
history
PB Ratio 43.95
CHRS's PB Ratio is ranked lower than
97% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. CHRS: 43.95 )
Ranked among companies with meaningful PB Ratio only.
CHRS' s PB Ratio Range Over the Past 10 Years
Min: 6.35  Med: 24.25 Max: 57.76
Current: 43.95
6.35
57.76
PS Ratio 5.63
CHRS's PS Ratio is ranked higher than
68% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. CHRS: 5.63 )
Ranked among companies with meaningful PS Ratio only.
CHRS' s PS Ratio Range Over the Past 10 Years
Min: 5.58  Med: 15.8 Max: 35.73
Current: 5.63
5.58
35.73
Current Ratio 2.86
CHRS's Current Ratio is ranked lower than
64% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. CHRS: 2.86 )
Ranked among companies with meaningful Current Ratio only.
CHRS' s Current Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.2 Max: 3.46
Current: 2.86
0.85
3.46
Quick Ratio 2.86
CHRS's Quick Ratio is ranked lower than
60% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CHRS: 2.86 )
Ranked among companies with meaningful Quick Ratio only.
CHRS' s Quick Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.2 Max: 3.46
Current: 2.86
0.85
3.46
Days Sales Outstanding 3.57
CHRS's Days Sales Outstanding is ranked higher than
94% of the 524 Companies
in the Global Biotechnology industry.

( Industry Median: 59.75 vs. CHRS: 3.57 )
Ranked among companies with meaningful Days Sales Outstanding only.
CHRS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.57  Med: 28.36 Max: 36.88
Current: 3.57
3.57
36.88

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 269.38
CHRS's Price-to-Net-Current-Asset-Value is ranked lower than
99% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. CHRS: 269.38 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CHRS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 9.22  Med: 180.55 Max: 351.88
Current: 269.38
9.22
351.88
Price-to-Tangible-Book 52.56
CHRS's Price-to-Tangible-Book is ranked lower than
98% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. CHRS: 52.56 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CHRS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 8.58  Med: 39.05 Max: 69.51
Current: 52.56
8.58
69.51
Price-to-Median-PS-Value 0.36
CHRS's Price-to-Median-PS-Value is ranked higher than
87% of the 673 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. CHRS: 0.36 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CHRS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.35  Med: 0.55 Max: 1.78
Current: 0.36
0.35
1.78
Earnings Yield (Greenblatt) % -10.91
CHRS's Earnings Yield (Greenblatt) % is ranked higher than
50% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. CHRS: -10.91 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CHRS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -11.6  Med: 0 Max: 1088.85
Current: -10.91
-11.6
1088.85

More Statistics

Revenue (TTM) (Mil) $190.1
EPS (TTM) $ -3.51
Short Percentage of Float18.45%
52-Week Range $14.00 - 31.98
Shares Outstanding (Mil)51.15

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 62 68 305
EPS ($) -4.96 -3.56 1.23
EPS without NRI ($) -4.96 -3.56 1.23
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CHRS

Headlines

Articles On GuruFocus.com
Coherus Biosciences' Humira Petition Denied Nov 08 2016 
A Look at Pharma Company Dermira's Performance Mar 27 2015 

More From Other Websites
Coherus BioSciences, Inc. :CHRS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
COHERUS BIOSCIENCES, INC. Financials Mar 17 2017
Coherus BioSciences, Inc. :CHRS-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017 Mar 16 2017
COHERUS BIOSCIENCES, INC. Files SEC form 10-K, Annual Report Mar 14 2017
Edited Transcript of CHRS earnings conference call or presentation 13-Mar-17 8:30pm GMT Mar 13 2017
Coherus BioSciences Inc Earnings Call scheduled for 4:30 pm ET today Mar 13 2017
Coherus BioSciences reports 4Q loss Mar 13 2017
Coherus BioSciences reports 4Q loss Mar 13 2017
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 13 2017
Coherus BioSciences Reports Fourth Quarter and Full Year 2016 Corporate Highlights and Financial... Mar 13 2017
Q4 2016 Coherus BioSciences Inc Earnings Release - After Market Close Mar 13 2017
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 06 2017
Coherus Addresses Trade Secret Action Filed by Amgen Mar 06 2017
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 03 2017
Statement by Coherus CEO Regarding Biosimilars User Fees Mar 02 2017
Coherus Announces CHS-1420 Pharmacokinetic Clinical Bioequivalence Study Meets Primary Endpoint Mar 02 2017
Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in March Mar 01 2017
Coherus BioSciences to Report Fourth Quarter and Full Year 2016 Financial Results on March 13th Feb 21 2017
Coherus BioSciences Announces New Employment Inducement Grants Feb 17 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)